Terms: = Breast cancer AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306
38 results:
1. Serum exosomal miR-3662 down-regulates the expression of RBMS3 to promote malignant progression and gemcitabine resistance of breast cancer cells.
Li X; Chu X; Wang H; Xiang L; Yue X
Chem Biol Drug Des; 2024 Mar; 103(3):e14488. PubMed ID: 38472166
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.
Hozumi C; Iizuka A; Ikeya T; Miyata H; Maeda C; Ashizawa T; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Muramatsu K; Sugino T; Shiomi A; Ohde Y; Bando E; Furukawa K; Sugiura T; Mukaigawa T; Nishimura S; Hirashima Y; Mitsuya K; Yoshikawa S; Tsubosa Y; Katagiri H; Niwakawa M; Yamaguchi K; Kenmotsu H; Akiyama Y
Cancer Genomics Proteomics; 2024; 21(1):88-101. PubMed ID: 38151294
[TBL] [Abstract] [Full Text] [Related]
3. Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study.
Zheng C; Liu Y; Wang X; Bi Z; Qiu P; Qiao G; Bi X; Shi Z; Zhang Z; Chen P; Sun X; Wang C; Zhu S; Meng X; Song Y; Qi Y; Li L; Luo N; Wang Y
Int J Surg; 2024 Mar; 110(3):1527-1536. PubMed ID: 38116673
[TBL] [Abstract] [Full Text] [Related]
4. Stage Analysis of breast cancer Metabolomics: A System Biology Approach.
Hosseinpour Z; Rezaei Tavirani M; Akbari ME
Asian Pac J Cancer Prev; 2023 May; 24(5):1571-1582. PubMed ID: 37247276
[TBL] [Abstract] [Full Text] [Related]
5. cancer Cells Promote Immune Regulatory Function of Macrophages by Upregulating Scavenger Receptor MARCO Expression.
Gu C; Wiest M; Zhang W; Halder K; Zurawski S; Zurawski G; Joo H; Oh S
J Immunol; 2023 Jul; 211(1):57-70. PubMed ID: 37212598
[TBL] [Abstract] [Full Text] [Related]
6. Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients.
Wu M; Lu L; Dai T; Li A; Yu Y; Li Y; Xu Z; Chen Y
Cancer Biomark; 2023; 36(1):83-96. PubMed ID: 36591654
[TBL] [Abstract] [Full Text] [Related]
7. Exploration of the immune microenvironment of breast cancer in large population cohorts.
Deng Y; Wang J; Hu Z; Cai Y; Xu Y; Xu K
Front Endocrinol (Lausanne); 2022; 13():955630. PubMed ID: 36046784
[TBL] [Abstract] [Full Text] [Related]
8. Effects of nonparticipation at previous screening rounds on the characteristics of screen-detected breast cancers.
Duijm LEM; Broeders MJM; Setz-Pels W; van Breest Smallenburg V; van Beek HC; Donkers-van Rossum AB; Slob MJ; Kuipers TP; Mann RM; Voogd AC
Eur J Radiol; 2022 Sep; 154():110391. PubMed ID: 35679699
[TBL] [Abstract] [Full Text] [Related]
9. Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.
Huang L; Liu X; Li L; Wang L; Wu N; Liu Z
Med Oncol; 2022 May; 39(5):92. PubMed ID: 35568771
[TBL] [Abstract] [Full Text] [Related]
10. Single Center Evaluation of Comparative breast Radiation dose of Contrast Enhanced Digital Mammography (CEDM), Digital Mammography (DM) and Digital breast Tomosynthesis (DBT).
Bicchierai G; Busoni S; Tortoli P; Bettarini S; Naro FD; De Benedetto D; Savi E; Bellini C; Miele V; Nori J
Acad Radiol; 2022 Sep; 29(9):1342-1349. PubMed ID: 35065889
[TBL] [Abstract] [Full Text] [Related]
11. CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.
Yi B; Wang S; Wang X; Liu Z; Zhang C; Li M; Gao S; Wei S; Bae S; Stringer-Reasor E; Wang L; Liu R
Oncogene; 2022 Jan; 41(2):268-279. PubMed ID: 34728806
[TBL] [Abstract] [Full Text] [Related]
12. A Machine Learning Model to Predict the Triple Negative breast cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract] [Full Text] [Related]
13. Single-cell profiling defines the prognostic benefit of CD39
Losurdo A; Scirgolea C; Alvisi G; Brummelman J; Errico V; Di Tommaso L; Pilipow K; Colombo FS; Fernandes B; Peano C; Testori A; Tinterri C; Roncalli M; Santoro A; Mazza EMC; Lugli E
Commun Biol; 2021 Sep; 4(1):1117. PubMed ID: 34552178
[TBL] [Abstract] [Full Text] [Related]
14. Detection significance of miR-3662, miR-146a, and miR-1290 in serum exosomes of breast cancer patients.
Li S; Zhang M; Xu F; Wang Y; Leng D
J Cancer Res Ther; 2021 Jul; 17(3):749-755. PubMed ID: 34269309
[TBL] [Abstract] [Full Text] [Related]
15. Host-derived lipids orchestrate pulmonary γδ T cell response to provide early protection against influenza virus infection.
Wang X; Lin X; Zheng Z; Lu B; Wang J; Tan AH; Zhao M; Loh JT; Ng SW; Chen Q; Xiao F; Huang E; Ko KH; Huang Z; Li J; Kok KH; Lu G; Liu X; Lam KP; Liu W; Zhang Y; Yuen KY; Mak TW; Lu L
Nat Commun; 2021 Mar; 12(1):1914. PubMed ID: 33772013
[TBL] [Abstract] [Full Text] [Related]
16. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract] [Full Text] [Related]
17. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract] [Full Text] [Related]
18. A parallel and cascade control system: magnetofection of miR125b for synergistic tumor-association macrophage polarization regulation and tumor cell suppression in breast cancer treatment.
Hu A; Chen X; Bi Q; Xiang Y; Jin R; Ai H; Nie Y
Nanoscale; 2020 Nov; 12(44):22615-22627. PubMed ID: 33150908
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of irf4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract] [Full Text] [Related]
20. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer.
Sigin VO; Kalinkin AI; Kuznetsova EB; Simonova OA; Chesnokova GG; Litviakov NV; Slonimskaya EM; Tsyganov MM; Ibragimova MK; Volodin IV; Vinogradov II; Vinogradov MI; Vinogradov IY; Kutsev SI; Strelnikov VV; Zaletaev DV; Tanas AS
Sci Rep; 2020 Jun; 10(1):9239. PubMed ID: 32514046
[TBL] [Abstract] [Full Text] [Related]
[Next]
